Trials / Recruiting
RecruitingNCT06795412
Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
A Phase 1/2, Open-label, Global, Multicenter, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 220 (estimated)
- Sponsor
- Pyxis Oncology, Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to determine the recommended Phase 2 doses (RP2D(s)) and maximum tolerated dose (MTD) of PYX-201 in combination with pembrolizumab for participants with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PYX-201 | Intravenous (IV) infusion. |
| DRUG | pembrolizumab | IV infusion. |
Timeline
- Start date
- 2025-04-15
- Primary completion
- 2027-12-06
- Completion
- 2027-12-06
- First posted
- 2025-01-28
- Last updated
- 2026-03-06
Locations
15 sites across 2 countries: United States, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06795412. Inclusion in this directory is not an endorsement.